Casein kinase II is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle.
Casein kinase II (CKII) is a ubiquitous serine/threonine protein kinase with many cellular functions, including participation in mitogenic signaling by cytoplasmic nuclear translocation (Lorenz, P., Pepperkok, R., Ansorge, W., and Pyerin, W. (1993) J. Biol. Chem. 268, 2733-2739). To examine whether cell compartment-specific availability is a requirement for CKII function during cell cycle progression, antibodies against CKII beta, the regulatory subunit of CKII, were microinjected into the cytoplasm or the nucleus of G0-synchronized human primary fibroblasts (IMR-90) at the time of mitogenic stimulation or at various intervals thereafter. Significant inhibition of the stimulation was obtained with both cytoplasmic and nuclear injections. The inhibition was reversible, was not observed with control antibodies, and was abolished by co-injection of purified CKII holoenzyme. The inhibition differed, however, in extent, duration, and cell cycle phase between cytoplasmic and nuclear injections. After cytoplasmic injection, inhibition reached 45-50% and was effective at two intervals within the first 2 h and at 12-16 h post-stimulation, i.e. at G0/G1 phase transition and at the G1/S phase boundary of the cell cycle. After injection into the nucleus, the inhibition was considerably stronger, reaching 80-85%, and was effective for the first 6 h post-stimulation, i.e. for the transition of G0/G1 phase and the adjoining first part of G1 phase. Cytoplasmic or nuclear injections within S phase affected neither DNA synthesis nor cell division. The data suggest that cell cycle transition from G0 to S phase requires the presence of a certain functional level of CKII at defined times and at defined cellular locations as follows: for transition of G0/G1 at both the nucleus and the cytoplasm, for transition of early G1 at the nucleus, and for transition of G1/S at the cytoplasm.
Pepperkok
R
R
German Cancer Research Center, Heidelberg.
Lorenz
P
P
Ansorge
W
W
Pyerin
W
W
D000818:Animals; D000906:Antibodies; D000911:Antibodies, Monoclonal; D047390:Casein Kinase II; D002453:Cell Cycle / Q000187:drug effects / Q000502:physiology*; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D004247:DNA / Q000096:biosynthesis; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D016193:G1 Phase; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D007700:Kinetics; D046911:Macromolecular Substances; D051379:Mice / Q000276:immunology; D017346:Protein Serine-Threonine Kinases / Q000276:immunology / Q000378:metabolism*; D011817:Rabbits / Q000276:immunology; D016192:Resting Phase, Cell Cycle; D016196:S Phase
D000906:Antibodies; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D046911:Macromolecular Substances; D004247:DNA; D047390:Casein Kinase II; D017346:Protein Serine-Threonine Kinases